Letters to the Editor
Vol. 16 No. 1 (2024): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
FEASIBILITY AND OUTCOME OF FIRST-LINE AUTOTRANSPLANT-BASED TREATMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS AGED > 65 YEARS: MONOCENTRIC RETROSPECTIVE REAL-WORLD ANALYSIS
Outcomes of ASCT in NDMM elderly fit patients
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: June 27, 2024
Accepted: July 22, 2024
Accepted: July 22, 2024
925
Views
628
Downloads
Authors
We performed a monocentric, retrospective real-world analysis (RWA) to evaluate the feasibility and the main results of an autologous stem cell transplantation (ASCT)-based program in a cohort of 90 newly diagnosed multiple myeloma patients aged > 65 years who were deemed eligible to such program on the basis of a simplified frailty score. Seventy-six patients received at least one ASCT and 14 patients received also the second. Median progression-free survival was 42 months and overall survival was 84 months. These results compare well with those of other RWAs, and pave the way to further improvements upon incorporation of an anti-CD38+ monoclonal antibody in the ASCT programs.
Downloads
Download data is not yet available.
Citations
Dimopoulos MA, Moreau P, Terpos E et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021;32:309-322.
Bergin K, Wellard C, Augustson B et al. Real-world utilization of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related disease registry (MRDR). Bone Marrow Transplant 2021;56:2533-2543.
Cavo M, Tacchetti P, Patriarca F et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:2075–85.
Facon T, Dimopoulos MA,Meulman N et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-20) trial. Leukemia 2020;34:224-233.
Kumar S, Moreau P, Bahlis BJ et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) vs lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 MAIA study. Blood 2022;140 (suppl.1):10150-10153.
Mateos MV, Dimopoulos M, Cavo M et al. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE. Clin Lymph Myel, Leuk 2021;21:785-791.
Mateos MV, San-Miguel J, Cavo M et al. Daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 ALCYONE study. Blood 2022;140 (suppl.1):10157-10159.
Moreau P, Attal M, Hulin C et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 2019;394:29-38.
Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–73.
How to Cite
“FEASIBILITY AND OUTCOME OF FIRST-LINE AUTOTRANSPLANT-BASED TREATMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS AGED > 65 YEARS: MONOCENTRIC RETROSPECTIVE REAL-WORLD ANALYSIS: Outcomes of ASCT in NDMM elderly fit patients” (2024) Mediterranean Journal of Hematology and Infectious Diseases, 16(1), p. e2024066. doi:10.4084/MJHID.2024.066.
Copyright (c) 2024 Paola Stefanoni, Monica Galli, laura paris, alessandro Rambaldi, Nicola Pittalis, Gianluca Cavallaro, Chiara Pavoni
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
